NCT04657068 2026-03-18
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1/2 Recruiting
Clinical Trials
15 trialsNCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed
NCT05281471 2026-03-18
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Phase 3 Recruiting
NCT07480954 2026-03-18
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT06824467 2026-03-13
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05417594 2026-03-12
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07024784 2026-03-04
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
Phase 2 Recruiting
NCT05579366 2026-03-03
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT03393884 2026-02-27
OVATION 2
Imunon
Phase 1/2 Active not recruiting
NCT05739981 2026-02-27
MRD
Imunon
Phase 1/2 Recruiting
NCT06915025 2026-02-27
OVATION-3
Imunon
Phase 3 Recruiting
NCT06890338 2026-02-24
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting
NCT05445778 2026-02-23
GLORIOSA
AbbVie
Phase 3 Recruiting
NCT05527184 2026-02-20
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
Phase 1 Active not recruiting